The aim of this study was to evaluate the metabolic effects of 12-week honey consumption on patients suffering from type 1 diabetes mellitus (DM). This was a randomized crossover clinical trial done in the National Institute for Diabetes and Endocrinology, Cairo, Egypt. Twenty patients of both sexes aged 4–18 years with type 1 DM and HbA1C<10% participated in the study. They were randomized into two equal groups (intervention to control and control to intervention). The dietary intervention was 12-week honey consumption in a dose of 0.5 mL/kg body weight per day. The main outcome measures were serum glucose, lipids, and C-peptide, and anthropometric measurements. None of participants were lost in follow-up. The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum glucose (FSG; P=.001), total cholesterol (P=.0001), serum triglycerides (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in fasting C-peptide (FCP; P=.0004) and 2-h postprandial C-peptide (PCP; P=.002). As possible long-term effects of honey after its withdrawal, statistically significant reductions in midarm circumference (P=.000), triceps skin fold thickness (P=.006), SSFT (P=.003), FSG (P=.005), 2-h postprandial serum glucose (P=.000), TG (P=.003), and HbA1C (P=.043), and significant increases in FCP (P=.002) and PCP (P=.003) were observed. This small clinical trial suggests that long-term consumption of honey might have positive effects on the metabolic derangements of type 1 DM.
Get full access to this article
View all access options for this article.
References
1.
BuschardK. What causes type 1 diabetes? Lessons from animal models. APMIS, 2011; 119,Suppl 132:1–19.
2.
EURODIAB ACE Study Group:. Variation and trends in incidence of childhood diabetes in Europe. Lancet, 2000; 355:873–876.
3.
BogdanovS, JurendicT, SieberR, GallmannP. Honey for nutrition and health: a review. J Am Coll Nutr, 2008; 27:677–689.
4.
WhiteJ. Composition of honey. Honey: A Comprehensive Survey. CraneE. Heinemann Edition: London, 1975; 157–206.
5.
AbdulrhmanM, El-HefnawyM, HusseinR, El-GoudAA. The glycemic and peak incremental indices of honey, sucrose and glucose in patients with type 1 diabetes mellitus: effects on C-peptide level-a pilot study. Acta Diabetol, 2011; 48:89–94.
6.
AgrawalOP, PachauriA, YadavH, UrmilaJ, GoswamyHM, ChapperwalAet al.Subjects with impaired glucose tolerance exhibit a high degree of tolerance to honey. J Med Food, 2007; 10:473–478.
7.
Al WailiNS. Natural honey lowers plasma glucose, Creactive protein, homocysteine, and blood lipids in healthy, diabetic, and hyperlipidemic subjects: comparison with dextrose and sucrose. J Med Food, 2004; 7:100–107.
8.
Ionescu-TirgovisteC, PopaE, SintuE, MihalacheN, ChetaD, MincuI. Blood glucose and plasma insulin responses to various carbohydrates in type 2 non-insulin-dependent diabetes. Diabetologia, 1983; 24:80–84.
9.
SamantaA, BurdenAC, JonesGR. Plasma glucose responses to glucose, sucrose, and honey in patients with diabetes mellitus: an analysis of glycemic and peak incremental indices. Diabet Med, 1985; 2:371–373.
10.
ShambaughP, WorthingtonV, HerbertJH. Differential effects of honey, sucrose, and fructose on blood sugar levels. J Manip Physiol Ther, 1990; 13:322–325.
11.
BahramiM, Ataie-JafariA, HosseiniS, ForuzanfarMH, RahmaniM, PajouhiM. Effects of natural honey consumption in diabetic patients: an 8-week randomized clinical trial. Int J Food Sci Nutr, 2009; 60:618–626Abstract.
12.
OizumiT, DaimonM, JimbuY, KamedaW, ArawakaN, YamaguchiHet al.A palatinose based formula improves glucose tolerance, serum free fatty acid levels and body fat composition. Tohoku J Exp Med, 2007; 212:91–99.
13.
DahlquistA, AuricchioS, SemenzaG, PraderA. Human intestinal disaccharidases and hereditary disaccharide intolerance: the hydrolysis of sucrose, isomaltose, palatinose (isomaltulose), and 1, 6-a-oligosaccharide (isomalto-oligosaccharide) preparation. J Clin Invest, 1963; 42:556–562.
14.
LinaBA, JonkerD, KozianowskiG. Isomaltulose (palatinose): a review of biological and toxicological studies. Food Chem Toxicol, 2002; 40:1375–1381.
15.
BergerB, StenströmG, SundkvistG. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest, 2000; 60:687–693.
16.
CraneE. A Book of Honey. Oxford University Press: Oxford, United Kingdom, 1980; 198.
17.
GharibNM, RasheedP. Anthropometry and body composition of school children in Bahrain. Ann Saudi Med, 2009; 29:258–269.
18.
KayeFP, HoltS, JanetteC. International table of glycemic index and glycaemic load values. Am J Clin Nutr, 2002; 76:5n56.
19.
GhorbaniA, VarediM, HadjzadehMA, OmraniGH. Type-1 diabetes induces depot-specific alterations in adipocyte diameter and mass of adipose tissues in the rat. Exp Clin Endocrinol Diabetes, 2010; 118:442–448Abstract.
20.
JacobAN, Adams-HuetB, RaskinP. The visceral and subcutaneous fat changes in type 1 diabetes: a pilot study. Diabetes Obes Metab, 2006; 8:524–530.
21.
SchmidtMI, WatsonRL, DuncanBB, MetcalfP, BrancatiFL, SharrettARet al.Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism, 1996; 45:699–706.
KennedyJ, ShavelleR, WangS, BudoffM, DetranoR. Coronary calcium and standard risk factors in symptomatic patients referred for coronary angiography. Am Heart J, 1998; 135:696–702.
24.
ConwayB, MillerRG, CostacouT, FriedL, KelseyS, EvansRWet al.Double-edged relationship between adiposity and coronary artery calcification in type 1 diabetes. Diab Vasc Dis Res, 2007; 4:332–339.
25.
CastigliaPT. Protein-energy malnutrition (kwashiorkor and marasmus)J Pediatr Health Care, 1996; 10:28–30.
26.
WatfordM. Small amounts of dietary fructose dramatically increase hepatic glucose uptake through a novel mechanism of glucokinase activation. Nutr Rev, 2002; 60:253–257.
27.
GrodskyGM, BattsAA, BennettLL, VcellaC, McwilliamsNB, SmithDFet al.Effect of carbohydrates on secretion of insulin from isolated rat pancreas. Am J Physiol, 1963; 205:638–644Abstract.
28.
MayesPA. Intermediary metabolism of fructose. Am J Clin Nutr, 1993; 58,5 Suppl:754S–765S.
29.
BusserollesJ, GueuxE, RockE, MazurA, RayssiguierY. Substituting honey for refined carbohydrates protects rats from hypertriglyceridemic and prooxidative effects of fructose. J Nutr, 2002; 132:3379–3382.
30.
NajafianM, Ebrahim-HabibiA, YaghmaeiP, ParivarK, LarijaniB. Core structure of flavonoids precursor as an antihyperglycemic and antihyperlipidemic agent: an in vivo study in rats. Acta Biochim Pol, 2010; 57:553–560.
31.
KimJS, KwonCS, SonKH. Inhibition of α-glucosidase and amylase by luteolin, a flavonoid. Biosci Biotechnol Biochem, 2000; 64:2458–2461.
32.
TaderaK, MinamiY, TakamatsuK, MatsuokaT. Inhibition of α-glucosidase and α-amylase by flavonoids. J Nutr Sci Vitaminol (Tokyo), 2006; 52:149–153.
33.
Lo PiparoE, ScheibH, FreiN, WilliamsonG, GrigorovM, ChouCJet al.Flavonoids for controlling starch digestion: structural requirements for inhibiting human α-amylase. J Med Chem, 2008; 51:3555–3561.
34.
AslanM, OrhanDD, OrhanN, SezikE, YesiladaE. A study of antidiabetic and antioxidant effects of Helichrysum graveolens capitulums in streptozotocin-induced diabetic rats. J Med Food, 2007; 10:396–400Abstract.
35.
LiW, DaiRJ, YuYH, LiL, WuCM, LuanWW, MengWWet al.Antihyperglycaemic effect of Cephalotaxus sinensis leaves and GLUT-4 translocation facilitating activity of its flavonoid constituents. Biol Pharm Bull, 2007; 30:1123–1129.
36.
SharmaB, BalomajumderC, RoyP. Hypoglycemic and hypolipidemic effects of flavonoid rich extract from Eugenia jambolana seeds on streptozotocin induced diabetic rats. Food Chem Toxicol, 2008; 46:2376–2383.
37.
PetrusK, SchwartzH, SontagG. Analysis of flavonoids in honey by HPLC coupled with coulometric electrode array detection and electrospray ionization mass spectrometry. Anal Bioanal Chem, 2011; 400:2555–2563.
38.
AndersonRA, ChengN, BrydenNA, PolanskyMM, ChengN, ChiJet al.Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes, 1997; 46:1786–1791Abstract.
39.
PolonskyKS, RubensteinAH. C-peptide as a measure of the secretion, hepatic extraction of insulin: pitfalls and limitations. Diabetes, 1984; 33:486–494Abstract
40.
SjöbergS, GunnarssonR, GjötterbergM, LefvertAK, PerssonA, OstmanJ. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1987; 30:208–213Abstract.
41.
ZerbiniG, MangiliR. LuziL: Higher post-absorptive C-peptide levels in Type 1 diabetic patients without renal complications. Diabet Med, 1999; 16:1048.
42.
PaneroF, NovelliG, ZuccoC, FornengoP, PerottoM, SegreOet al.Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care, 2009; 32:301–305.
43.
Bonnefont-RousselotD, BastardJP, JaudonMC, DelattreJ. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab, 2000; 26:163–176.
44.
FrankelS, RobinsonG, BerenbaumM. Antioxidant capacity and correlated characteristics of 14 unifloral honeys. J Apic Res, 1998; 37:27–31.
45.
GheldofN, EngesethN. Antioxidant capacity of honeys from various floral sources based on the determination of oxygen radical absorbance capacity and inhibition of in vitro lipoprotein oxidation in human serum samples. J Agric Food Chem, 2002; 50:3050–3055.
46.
Al WailiN, BoniN. Natural honey lowers plasma prostaglandin concentrations in normal individuals. J Med Food, 2003; 6:129–133.
47.
ZeinaB, OthmanO, Al-AssadS. Effect of honey versus thyme on Rubella virus survival in vitro. J Altern Complement Med, 1996; 2:345–348.
48.
OlofssonTC, VásquezA. Detection and identification of a novel lactic acid bacterial flora within the honey stomach of the honeybee Apis mellifera. Curr Microbiol, 2008; 57:356–363.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
